Bayer and NextRNA collaboration
Bayer and NextRNA Therapeutics have entered a strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) for oncology treatments
This partnership aims to advance two novel oncology programs that address high unmet medical needs by disrupting the interaction between lncRNAs and RNA-binding proteins (RBPs). NextRNA will receive up to $547 million in payments, including research funding and milestone payments, and both companies will collaborate on developing the first program, while Bayer has the option to select a second target identified by NextRNA. The agreement leverages NextRNA's unique platform and expertise in lncRNA biology to create transformative cancer therapies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins